Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31145667 | 1.00 | MEN1 (0.40) | MEN1KMT2AGAAMAPTPRCP | |
| SCHEMBL19676469 | 0.77 | PNMT (0.41) | MEN1KMT2AGAAMAPTPRCP | |
| SCHEMBL6075506 | 0.75 | GAA (0.43) | MEN1KMT2AGAAMAPTPRCP | |
| SCHEMBL29239505 | 0.75 | MEN1 (0.40) | MEN1KMT2AGAAMAPTPRCP | |
| SCHEMBL1436282 | 0.75 | MEN1 (0.40) | MEN1KMT2AGAAMAPTPRCP | |
| SCHEMBL14730122 | 0.75 | ALOX15 (0.41) | MEN1KMT2AGAAMAPTPRCP | |
| SCHEMBL9672402 | 0.75 | MEN1 (0.41) | MEN1KMT2AGAAMAPTALOX15 | |
| SCHEMBL17454501 | 0.73 | CHRNB2 (0.35) | — | |
| SCHEMBL2658519 | 0.73 | GAA (0.46) | MEN1KMT2AGAAMAPTPRCP | |
| SCHEMBL9955369 | 0.73 | CHRNB2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108018037-B | 6, 8-methano tetrahydroquinazoline-2-amine Schiff base type iron ion fluorescent probe and preparation method and application thereof | 南京林业大学 | 2020-01-24 | — | — | CN | claimed |
| CN-108018037-A | 6,8- endo-methylene group tetrahydro quinazoline -2- amine Schiff bases iron ion fluorescence probes and its preparation method and application | 南京林业大学 | 2018-05-11 | — | — | CN | claimed |
| CN-105085413-B | Tetrahydroquinazoline-2-schiff base compounds as well as synthesis method and application thereof | 南京林业大学 | 2017-05-10 | — | — | CN | claimed |
| CN-105085413-A | Tetrahydroquinazoline-2-schiff base compounds as well as synthesis method and application thereof | UNIV NANJING FORESTRY | 2015-11-25 | — | — | CN | claimed |
| CN-116165186-A | In-situ fluorescence chromogenic reaction dual-mode detection Cu based on dopamine and isophthaol 2+ And Ag + Is a method of (2) | 南昌航空大学 | 2023-05-26 | — | — | CN | disclosed |
| CN-108018037-A | 6,8- endo-methylene group tetrahydro quinazoline -2- amine Schiff bases iron ion fluorescence probes and its preparation method and application | 南京林业大学 | 2018-05-11 | — | — | CN | disclosed |
| CN-108018037-A | 6,8- endo-methylene group tetrahydro quinazoline -2- amine Schiff bases iron ion fluorescence probes and its preparation method and application | 南京林业大学 | 2018-05-11 | — | — | CN | disclosed |
| CN-105085413-B | Tetrahydroquinazoline-2-schiff base compounds as well as synthesis method and application thereof | 南京林业大学 | 2017-05-10 | — | — | CN | disclosed |
| CN-105085413-A | Tetrahydroquinazoline-2-schiff base compounds as well as synthesis method and application thereof | UNIV NANJING FORESTRY | 2015-11-25 | — | — | CN | disclosed |
| WO-2012085166-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-06-28 | — | — | WO | disclosed |
| US-20100298289-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | UCB PHARMA, S.A. (BE) | 2010-11-25 | — | — | US | disclosed |
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | MEN1 734/4885KMT2A 693/4885GAA 484/4885 |
| US-20100298289-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | HRH4, HRH2, HRH3 | MEN1 1111/4885KMT2A 802/4885GAA 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.